TY - JOUR
T1 - Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer
AU - Cooley, Lauren Folgosa
AU - McLaughlin, Kimberly A.
AU - Meeks, Joshua J.
N1 - Funding Information:
Disclosure: L.F. Cooley and K.A. McLaughlin have nothing to disclose. J.J. Meeks is a consultant for Ferring and Astra Zeneca, receives honoraria from Janssen and Cold Genesys, and receives research funding from Epizyme, Abbvie, and Tesaro, with clinical trial support from Merck.Funding: J.J. Meeks is supported by Department of Veterans Affairs (BX003692) and Department of Defense (W81XWH-18-0257) and an award from the John P. Hanson Foundation for Cancer Research (Milwaukee, WI).
Publisher Copyright:
© 2019
PY - 2020/2
Y1 - 2020/2
N2 - Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.
AB - Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.
KW - BCG
KW - Bladder cancer
KW - Genomics
KW - Immunotherapy
KW - Mutation
UR - http://www.scopus.com/inward/record.url?scp=85075073932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075073932&partnerID=8YFLogxK
U2 - 10.1016/j.ucl.2019.09.006
DO - 10.1016/j.ucl.2019.09.006
M3 - Review article
C2 - 31757298
AN - SCOPUS:85075073932
SN - 0094-0143
VL - 47
SP - 35
EP - 46
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
IS - 1
ER -
